A new technique has been developed by statisticians to help doctors optimize dosing new cancer treatments in phase I/II clinical trials.
A genetically engineered herpes virus can be used to kill off skin cancer cells and galvanize the immune system, according to phase 3 clinical trial data.
Clinical trial results showed good performance employing the investigational drug brigatinib against ALK-positive non-small cell lung cancer (NSCLC).
Drugs that are more commonly used to treat melanoma can also be use to help some individuals with lung cancer, research indicates.
[Blood and Lymphatic Cancer: Targets and Therapy] The article discusses the history, use, and evolution of rituximab in the treatment of CLL and examines the next generation CD20 antibodies ofatumumab and obinutuzumab.
Personalized melanoma vaccines can be used to galvanize a powerful immune response against unique mutations in patients' tumors, according to early data in a first-in-people clinical trial.
Adrenal cancer is among the more rare and aggressive forms of cancer, but new research indicates the possibility of personalized treatment.
A subset of adrenal cancer patients responded well to drug treatment in a phase 3 trial, giving some hope for addressing this aggressive form of cancer.
A phase 3 trial of brentuximab vedotin (BV) showed that adults with hard-to-treat Hodgkin lymphoma given BV after stem cell transplantation survived without the disease progression for twice as long as when a placebo was administered.
New evidence indicates that combining chemotherapy with radiation therapy may be the best option for people with a low-grade form of brain cancer.
A previous history of cancer cancer did not impact clinical outcomes in advanced lung cancer patients and these patients therefore should be considered for inclusion in clinical trials, according to a study .
The antibody MPDL3280A, which blocks the protein PD-L1, resulted in tumor shrinkage in slightly over half of tested patients with advanced bladder cancer.
Among premenopausal women with early stage, HR-positive breast cancer, the addition of ovarian suppression to tamoxifen reduced breast cancer recurrence.
The International Breast Cancer Intervention Study-I (IBIS-I) trial found that tamoxifen significantly decreased the incidence of all breast cancers, according to data presented at the 2014 San Antonio Breast Cancer Symposium.
Pembrolizumab was well tolerated and yielded durable responses in patients with metastatic triple-negative breast cancer, according to recent trial data.
A new drug that targets common cancer-causing genetic mutations in patients with non-small cell lung cancer (NSCLC), and a type of the mutation responsible for treatment resistance, has shown promising results in a phase I/II clinical trial.
The first drug designed to inhibit the cancer-causing activity of a mutated enzyme known as isocitrate dehydrogenase (IDH) 1 has shown clinical activity in patients with advanced acute myeloid leukemia (AML) with the IDH1 mutation.
The anticancer drug galeterone has proved successful in lowering prostate-specific antigen levels in men with castration-resistant prostate cancer (CRPC).
A method to determine which patients with ovarian cancer are more likely to respond well to the new anticancer drug rucaparib has been discovered.
Previously, patients with advanced colorectal cancer driven by a mutated version of the BRAF gene have had limited treatment options, but results from a multicenter clinical trial suggest a new option.
Patients with B-cell non-Hodgkin lymphomas and advanced solid tumors have responded to a new drug that is being tested for the first time in humans in a phase I clinical trial.
Latina patients with breast cancer had much more awareness of clinical trials versus women who received the typical information.
An investigational personalized cellular therapy was found to have achieved remission in some 90% of children and adults with acute lymphoblastic leukemia (ALL) tested.
A new drug breakthrough could extend the life of people living with glioblastoma, the most aggressive type of brain cancer.
A new drug in development, known as DTP3, has killed myeloma cells in laboratory tests in human cells and mice.
Clinical trials could benefit from a greater number of participants with a dedicated cooperative network to support rural community cancer centers.
A history of prior cancer can exclude many individuals from participation in clinical trails related to lung cancer, even when the prior cancer is unlikely to interfere with treatment outcomes.
Approximately one fifth of patients with malignant pleural mesothelioma have cancer cells that express a protein called programmed cell-death ligand 1 (PD-L1), which has been associated with poorer outcomes.
Targeting BRAF V600E/K mutation-positive melanoma with dabrafenib in combination with trametinib achieves longer overall survival and impoved response rates, compared to treatment with vemurafenib alone.
The BRAF inhibitor dabrafenib has significant antitumor activity in patients with advanced BRAF V600E mutant non-small cell lung cancer (NSCLC) whose disease has progressed after chemotherapy, according to phase II data.
- Breakthrough supportive care: Overcoming cancer anorexia/cachexia
- Study uses dog sledding to demonstrate benefits of adapted physical activities for children with cancer
- Even light drinking puts women at greater risk to develop cancer
- Efficacy and safety of docetaxel for advanced non-small-cell lung cancer: A meta-analysis of Phase III randomized controlled trials
- Cabozantinib granted Breakthrough Therapy Designation for kidney cancer
- Religiousness and spirituality have a significant impact on cancer patients' overall health and outcomes
- Dietary intervention primes triple-negative breast cancer cells for targeted therapy
- Lung cancer patients who stop smoking live longer
- Review examines strategies for hospital room surface cleanliness
- Appropriate use of tomosynthesis mammography
- Two-cycle technique improves determining optimal treatment doses in clinical trials
- Synchronous resection of primary colorectal tumor, liver metastases safe in some patients
- Prostate cancer not likely to be cause of death in men with low-risk disease
- Among patients with myeloma undergoing chemo, high exercise compliance linked with reduced fatigue
- Oral palonosetron noninferior to IV formulation for CINV prevention
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|